Notice ID: 65b3f50ad556415db187d3eea9070be6Special Notice
Notice of Intent to Sole Source; Monument Medical
Archived on November 30, 2024. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 10:00 AM UTC−05:00
- Posted
- October 25, 2024
- Notice type
- Special Notice
- Set-aside
- Total Small Business Set-Aside (FAR 19.5)
- NAICS
- 339112: Surgical and Medical Instrument Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH - CC
- Place of performance
- Bethesda, MD
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 25-000116
- Notice ID
- 65b3f50ad556415db187d3eea9070be6
Description
The purpose of this acquisition is to purchase compounded INTRAVENOUS (IV) Narcotics for patient Care at the National Institutes of Health (NIH) Clinical Center (CC). Product Service Code: 6515 Medical Instruments, Equipment, and Supplies NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing Place of Performance: Bethesda, MD 20892 USA POTS: 25-000116 Description: This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institutes of Health (NIH) intends to award a firm fixed price purchase order to QuVA Pharma, Inc., located at 3 Sugar Creek Center Blvd, Ste 250, Sugar Land, TX 77478, on a sole source award basis to provide Intravenous Narcotics to the National Institutes of Health. Below is a description of the item(s): Sterile compounded products that meet the quality expectations to provide to National Institutes of Health Clinical Center (NIH CC) patients on an ongoing basis. The manufacturer (QUVA PHARMA, INC) has not designated other distributors of IV narcotics in the U.S. Market research has been conducted with only two responses, from QUVA, the known COMPOUNDER and distributor for these IV narcotics. Through trade shows, continuous learning seminars and trade journals, the CC Pharmacy Department stays abreast of the industry and is current on the availability of singular distribution outlets for these medications. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by November 15th, 2024 at 10am EST.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
25-000116- Special NoticeCurrentOct 25, 2024
Notice of Intent to Sole Source; Monument Medical
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
25-000116
Archive Date
Nov 30, 2024
Office Address
BETHESDA, MD, 20892